Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial

  • Abdelkefi A
  • Ladeb S
  • Torjman L
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and less than 60 years of age, were randomly assigned to receive either tandem transplantation up-front [Arm A, n=97] or one autologous stem cell transplantation followed by a maintenance therapy with thalidomide (day +90, 100 mg per day during 6 months) [Arm B, n=98]. Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m(2)) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6-46 months), the 3-year overall survival was 65% in arm A, and 85% in arm B (P= .04). The 3-year progression-free survival was 57% in arm A, and 85% in arm B (P= .02). Up-front single autologous transplant followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients, and appears superior to tandem transplant in this setting. This study was registered at (NCT 00207805).

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

There are no full text links


  • A Abdelkefi

  • S Ladeb

  • L Torjman

  • T Ben Othman

  • A Lakhal

  • N Ben Romdhane

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free